Legendary Investment Corporation Shatters Records with Momentous $4.0 Million Offering

Daxor Corporation (Nasdaq: DXR) is proud to announce the pricing of its underwritten public offering of 410,260 shares of common stock at $9.75 per share. With an impressive gross amount of $4.0 million in proceeds before deducting associated fees, the Company is primed to utilize these funds to further the development of its innovative blood volume measurement technology.

Maxim Group LLC and Joseph Gunnar & Co., LLC have partnered to serve as the lead service providers for an upcoming offering, with Maxim Group acting as the sole book-running manager and Joseph Gunnar & Co., LLC acting as co-manager.

Daxor is excited to use the proceeds from this offering to bring our vision for the future to life. We plan to use the funds to develop our products, fund capital expenditures, make investments, and even potentially repay some of our outstanding debts. With this offering, we have the opportunity to grow our business, make acquisitions, and explore new solutions and technologies.

Daxor has given the underwriters an amazing 45-day window to buy an extra 61,539 shares of its common stock. If all things go according to plan, this offering is set to wrap up on or around May 24, 2023, after all of the customary closing conditions have been met.

The U.S. Securities and Exchange Commission filed a shelf registration statement (Form N-2) with File Nos.333-255212 and 811-22684 on April 13, 2021, and it became effective on July 16, 2021. Prospective investors can find more details on the public offering in the preliminary prospectus supplement and accompanying prospectus filed with the SEC. You can also obtain copies of the prospectus from Maxim Group LLC at the 300 Park Avenue, 16th Floor, New York, NY 10022.

Before you invest, make sure to read the prospectus so you have all the information you need about Daxor and the public offering. The final terms of the offering will be disclosed in the final prospectus supplement once it’s filed with the SEC.

Before investing in these securities, please be sure that such action is in compliance with the laws of your state or jurisdiction. We are not offering to sell or buy these securities – any solicitation or sale of these securities is strictly prohibited.

About Daxor

Daxor Corporation (Nasdaq: DXR) is revolutionising the healthcare industry with its state-of-the-art blood volume measurement technology – the BVA-100® (Blood Volume Analyzer). This diagnostic tool, cleared by the FDA, is proven to provide safe, accurate, and objective results based on patient-specific norms.

Over 60,000+ tests have been conducted in major hospitals across the U.S., resulting in notable improvements in mortality and readmission rates for heart failure and critical care, among other medical conditions.

Currently, Daxor is also involved in several NIH-backed multicenter trials for COVID-19 and heart failure, and has a contract to develop new devices for combat casualty care with the U.S. Department of Defense. At Daxor, we strive to achieve optimal fluid management with blood volume analysis, and ultimately make optimal blood volume a reality for everyone.

Leave a Comment